Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04801797 · ClinicalTrials.gov registry record · Phase 2

Venetoclax + Azacitidine vs. Induction Chemotherapy in AML

A Phase 2 study of Acute Myeloid Leukemia, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
Phase 2
Development phase
172
Enrollment target
9
Study locations

NCT04801797 is a Phase 2 study of Acute Myeloid Leukemia that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 172 participants, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (50% higher). The trial reports 9 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04801797, a Phase 2 study of Acute Myeloid Leukemia, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
Phase 2
Development phase
172 participants
Enrollment target
9
Study locations

Study Summary

This research is being done to assess the therapeutic activity of a promising combination (azacitidine and venetoclax) versus conventional cytotoxic chemotherapy in induction-eligible patients with acute myeloid leukemia. This study involves the following: * Venetoclax and azacitidine (investigational combination) * Cytarabine and idarubicin or daunorubicin (per standard of care) or Liposomal daunorubicin and cytarabine (per standard of care)

Conditions Studied

Acute Myeloid Leukemia

Interventions

  • DRUG Venetoclax
  • DRUG Cytarabine
  • DRUG Idarubicin
  • DRUG Daunorubicin
  • DRUG Liposomal daunorubicin and cytarabine

Study Locations (9)

California

  • City of Hope - Duarte
  • Stanford Cancer Center - Palo Alto
  • University of California - Davis - Sacramento

Massachusetts

  • Massachusetts General Hospital Cancer Center - Boston
  • Beth Israel Deaconess Medical Center - Boston
  • Dana-Farber Cancer Institute - Boston

North Carolina

  • Atrium Health Levine Cancer Institute - Charlotte

Ohio

  • Ohio State University Medical Center - Columbus

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 172 participants
Start Date 2021-05-20
Est. Completion 2028-01-01
Phase Phase 2

Sponsor

Massachusetts General Hospital

2,032 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04801797

The ClinicalTrials.gov registry entry for NCT04801797 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (50% higher). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Venetoclax is the first listed.

NCT04801797 reports 9 study locations spanning 5 distinct geographic areas - top geographies include California, Massachusetts, North Carolina.

Frequently Asked Questions

What is clinical trial NCT04801797 about?

NCT04801797 is a clinical study titled "Venetoclax + Azacitidine vs. Induction Chemotherapy in AML". This research is being done to assess the therapeutic activity of a promising combination (azacitidine and venetoclax) versus conventional cytotoxic chemotherapy in induction-eligible patients with acute myeloid leukemia. This study involves the following: * Venetoclax and azacitidine (investigati...

What is the current status of trial NCT04801797?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2021-05-20. Estimated completion is 2028-01-01.

What conditions does trial NCT04801797 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia.

What interventions are being tested in trial NCT04801797?

The interventions under investigation include: Venetoclax (DRUG), Cytarabine (DRUG), Idarubicin (DRUG), Daunorubicin (DRUG), Liposomal daunorubicin and cytarabine (DRUG).

Who is sponsoring clinical trial NCT04801797?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04801797 being conducted?

This trial has 9 study locations across California, Massachusetts, North Carolina, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.